Trial Outcomes & Findings for Study of RP-3500, Camonsertib, in Advanced Solid Tumors (NCT NCT04497116)
NCT ID: NCT04497116
Last Updated: 2025-10-21
Results Overview
Treatment-emergent adverse events (TEAEs) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. AEs are considered related to treatment if the relationship to camonsertib or the other combination drug (in the study regimen) is "Related" (include unknown relationship) as indicated on the AE eCRF page based on investigator's assessment.
Recruitment status
COMPLETED
Study phase
PHASE1/PHASE2
Target enrollment
276 participants
Primary outcome timeframe
Start of treatment to 30 days post last dose, up to 1 year
Results posted on
2025-10-21
Participant Flow
Participant milestones
| Measure |
Cam<=80 5/2
Module 1 Dose level 1: Camonsertib 5 days on 2 days off Schedule \<=80 mg/day
|
Cam100 5/2
Module 1 Dose Schedule 2:Camonsertib Monotherapy 5 days on 2 days off Schedule, 100 mg QD
|
Cam120 5/2
Module 1 Dose Schedule 3: Camonsertib Monotherapy 5 days on 2 days off Schedule, 120 mg QD
|
Cam160 5/2
Module 1 Dose Schedule 4: Camonsertib Monotherapy 5 days on 2 days off Schedule, 160 mg QD
|
Cam80BID 5/2
Module 1 Dose Schedule 5: Camonsertib Monotherapy 5 days on 2 days off Schedule, 80 mg BID
|
Cam40BID 3/4
Module 1 Dose Schedule 6: Camonsertib Monotherapy 3 days on 4 days off Schedule, 40 mg BID
|
Cam60BID 3/4
Module 1 Dose Schedule 7: Camonsertib Monotherapy 3 days on 4 days off Schedule, 60 mg BID
|
Cam120 3/4
Module 1 Dose Schedule 8: Camonsertib Monotherapy 3 days on 4 days off Schedule, 120 mg QD
|
Cam160 3/4
Module 1 Dose Schedule 9: Camonsertib Monotherapy 3 days on 4 days off Schedule, 160 mg QD
|
Cam160 2/1w
Module 1 Dose Schedule 10: Camonsertib Monotherapy 3 days on 4 days off Schedule, 160 mg QD, 2 weeks on 1 week off
|
Cam200 2/1w
Module 1 Dose Schedule 11: Camonsertib Monotherapy 3 days on 4 days off Schedule, 200 mg QD, 2 weeks on 1 week off
|
Tala0.5+Cam25
Module 3a Dose Schedule 1: Talazoparib daily, Camonsertib Day 5 -7 , 3 weeks on schedule, 0.5mg QD Talazoparib + 25mg BID Camonsertib
|
Tala0.25+Cam25
Module 3a Dose Schedule 2: Talazoparib daily, Camonsertib Day 5 - 7, 3 weeks on: 0.25mg QD Talazoparib + 25mg BID Camonsertib
|
Tala0.25+Cam50
Module 3a Dose Schedule 3: Talazoparib daily, Camonsertib Day 5 - 7, 1 week on 1 week off Schedule, 0.25mg QD Talazoparib + 50mg QD Camonsertib
|
Tala0.25+Cam80
Module 3a Dose Schedule 4: Talazoparib daily, Camonsertib Day 5 - 7, 1 week on 1 week off Schedule, 0.25mg QD Talazoparib + 80mg QD Camonsertib
|
Gem400+Cam80 2/1
Module 4 Dose Schedule 1: Gemcitabine 400 mg/m2 + Camonsertib 80 mg QD 3 days on 4 days off, 2 weeks on 1 week off
|
Gem600+Cam80
Module 4 Dose Schedule 2: Gemcitabine 600 mg/m2 + Camonsertib 80 mg QD, 3 days on 4 days off, 2 weeks on 1 week off
|
Gem800+Cam80
Module 4 Dose Schedule 3: Gemcitabine 800 mg/m2 + Camonsertib 80 mg QD, 3 days on 4 days off, 2 weeks on 1 weeks off
|
Gem1000+Cam80
Module 4 Dose Schedule 4: Gemcitabine 1000 mg/m2 + Camonsertib 80 mg QD, 3 days on 4 days off, 2 weeks on 1 week off
|
Gem400+Cam80 1/1w
Module 4 Dose Schedule 5: Gemcitabine 400 mg/m2 + Camonsertib 80 mg QD, 3 days on 4 days off, 1 week on 1 week off
|
Gem400+Cam80 2/5
Module 4 Dose Schedule 6: Gemcitabine 400 mg/m2 + Camonsertib 80mg QD, 2 days on 5 days off, 1 week on 1 week off
|
Gem100+Cam120
Module 4 Dose Schedule 7: Gemcitabine 100mg/m2 + Camonsertib 120 mg QD, 2 days on 5 days off, 2 weeks on 1 week off
|
Gem100+Cam80mg
Module 4 Dose Schedule 8: Gemcitabine 100 mg/m2 + Camonsertib 80 mg QD, 2 days on 5 days off, 2 weeks on 1 week off
|
Gem200+Cam80 2/1w
Module 4 Dose Schedule 9: Gemcitabine 200 mg/m2 + Camonsertib 80 mg QD, 2 days on 5 days off, 2 weeks on 1 week off
|
Gem200+Cam80 1/1w
Module 4 Dose Schedule 10: Gemcitabine 200 mg/m2 + Camonsertib 80 mg QD, 2 days on 5 days off, 1 week on 1 week off
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
7
|
8
|
6
|
3
|
1
|
1
|
4
|
25
|
67
|
30
|
5
|
2
|
3
|
6
|
32
|
5
|
6
|
2
|
5
|
28
|
3
|
2
|
6
|
12
|
7
|
|
Overall Study
COMPLETED
|
1
|
3
|
3
|
1
|
0
|
0
|
0
|
5
|
13
|
8
|
0
|
1
|
1
|
3
|
7
|
1
|
1
|
0
|
0
|
5
|
0
|
0
|
0
|
2
|
0
|
|
Overall Study
NOT COMPLETED
|
6
|
5
|
3
|
2
|
1
|
1
|
4
|
20
|
54
|
22
|
5
|
1
|
2
|
3
|
25
|
4
|
5
|
2
|
5
|
23
|
3
|
2
|
6
|
10
|
7
|
Reasons for withdrawal
| Measure |
Cam<=80 5/2
Module 1 Dose level 1: Camonsertib 5 days on 2 days off Schedule \<=80 mg/day
|
Cam100 5/2
Module 1 Dose Schedule 2:Camonsertib Monotherapy 5 days on 2 days off Schedule, 100 mg QD
|
Cam120 5/2
Module 1 Dose Schedule 3: Camonsertib Monotherapy 5 days on 2 days off Schedule, 120 mg QD
|
Cam160 5/2
Module 1 Dose Schedule 4: Camonsertib Monotherapy 5 days on 2 days off Schedule, 160 mg QD
|
Cam80BID 5/2
Module 1 Dose Schedule 5: Camonsertib Monotherapy 5 days on 2 days off Schedule, 80 mg BID
|
Cam40BID 3/4
Module 1 Dose Schedule 6: Camonsertib Monotherapy 3 days on 4 days off Schedule, 40 mg BID
|
Cam60BID 3/4
Module 1 Dose Schedule 7: Camonsertib Monotherapy 3 days on 4 days off Schedule, 60 mg BID
|
Cam120 3/4
Module 1 Dose Schedule 8: Camonsertib Monotherapy 3 days on 4 days off Schedule, 120 mg QD
|
Cam160 3/4
Module 1 Dose Schedule 9: Camonsertib Monotherapy 3 days on 4 days off Schedule, 160 mg QD
|
Cam160 2/1w
Module 1 Dose Schedule 10: Camonsertib Monotherapy 3 days on 4 days off Schedule, 160 mg QD, 2 weeks on 1 week off
|
Cam200 2/1w
Module 1 Dose Schedule 11: Camonsertib Monotherapy 3 days on 4 days off Schedule, 200 mg QD, 2 weeks on 1 week off
|
Tala0.5+Cam25
Module 3a Dose Schedule 1: Talazoparib daily, Camonsertib Day 5 -7 , 3 weeks on schedule, 0.5mg QD Talazoparib + 25mg BID Camonsertib
|
Tala0.25+Cam25
Module 3a Dose Schedule 2: Talazoparib daily, Camonsertib Day 5 - 7, 3 weeks on: 0.25mg QD Talazoparib + 25mg BID Camonsertib
|
Tala0.25+Cam50
Module 3a Dose Schedule 3: Talazoparib daily, Camonsertib Day 5 - 7, 1 week on 1 week off Schedule, 0.25mg QD Talazoparib + 50mg QD Camonsertib
|
Tala0.25+Cam80
Module 3a Dose Schedule 4: Talazoparib daily, Camonsertib Day 5 - 7, 1 week on 1 week off Schedule, 0.25mg QD Talazoparib + 80mg QD Camonsertib
|
Gem400+Cam80 2/1
Module 4 Dose Schedule 1: Gemcitabine 400 mg/m2 + Camonsertib 80 mg QD 3 days on 4 days off, 2 weeks on 1 week off
|
Gem600+Cam80
Module 4 Dose Schedule 2: Gemcitabine 600 mg/m2 + Camonsertib 80 mg QD, 3 days on 4 days off, 2 weeks on 1 week off
|
Gem800+Cam80
Module 4 Dose Schedule 3: Gemcitabine 800 mg/m2 + Camonsertib 80 mg QD, 3 days on 4 days off, 2 weeks on 1 weeks off
|
Gem1000+Cam80
Module 4 Dose Schedule 4: Gemcitabine 1000 mg/m2 + Camonsertib 80 mg QD, 3 days on 4 days off, 2 weeks on 1 week off
|
Gem400+Cam80 1/1w
Module 4 Dose Schedule 5: Gemcitabine 400 mg/m2 + Camonsertib 80 mg QD, 3 days on 4 days off, 1 week on 1 week off
|
Gem400+Cam80 2/5
Module 4 Dose Schedule 6: Gemcitabine 400 mg/m2 + Camonsertib 80mg QD, 2 days on 5 days off, 1 week on 1 week off
|
Gem100+Cam120
Module 4 Dose Schedule 7: Gemcitabine 100mg/m2 + Camonsertib 120 mg QD, 2 days on 5 days off, 2 weeks on 1 week off
|
Gem100+Cam80mg
Module 4 Dose Schedule 8: Gemcitabine 100 mg/m2 + Camonsertib 80 mg QD, 2 days on 5 days off, 2 weeks on 1 week off
|
Gem200+Cam80 2/1w
Module 4 Dose Schedule 9: Gemcitabine 200 mg/m2 + Camonsertib 80 mg QD, 2 days on 5 days off, 2 weeks on 1 week off
|
Gem200+Cam80 1/1w
Module 4 Dose Schedule 10: Gemcitabine 200 mg/m2 + Camonsertib 80 mg QD, 2 days on 5 days off, 1 week on 1 week off
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
Lost to Follow-up
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
Overall Study
Sponsor decision to terminate study
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
Death
|
4
|
5
|
2
|
2
|
1
|
1
|
3
|
10
|
37
|
17
|
2
|
1
|
1
|
3
|
18
|
3
|
2
|
1
|
4
|
17
|
1
|
0
|
3
|
5
|
4
|
|
Overall Study
Withdrawal by Subject
|
1
|
0
|
1
|
0
|
0
|
0
|
0
|
7
|
14
|
3
|
3
|
0
|
1
|
0
|
7
|
1
|
3
|
1
|
1
|
5
|
2
|
2
|
2
|
4
|
3
|
|
Overall Study
Physician Decision
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
|
Overall Study
Clinical Progression Related
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Baseline Characteristics
Study of RP-3500, Camonsertib, in Advanced Solid Tumors
Baseline characteristics by cohort
| Measure |
Module 1 Dose Schedule 1
n=7 Participants
Camonsertib 5 days on 2 days off Schedule \<=80 mg/day
|
Module 1 Dose Schedule 2
n=8 Participants
Camonsertib Monotherapy 5 days on 2 days off Schedule, 100 mg QD
|
Module 1 Dose Schedule 3
n=6 Participants
Camonsertib Monotherapy 5 days on 2 days off Schedule, 120 mg QD
|
Module 1 Dose Schedule 4
n=3 Participants
Camonsertib Monotherapy 5 days on 2 days off Schedule, 160 mg QD
|
Module 1 Dose Schedule 5
n=1 Participants
Camonsertib Monotherapy 5 days on 2 days off Schedule, 80 mg BID
|
Module 1 Dose Schedule 6
n=1 Participants
Camonsertib Monotherapy 3 days on 4 days off Schedule, 40 mg BID
|
Module 1 Dose Schedule 7
n=4 Participants
Camonsertib Monotherapy 3 days on 4 days off Schedule, 60 mg BID
|
Module 1 Dose Schedule 8
n=25 Participants
Camonsertib Monotherapy 3 days on 4 days off Schedule, 120 mg QD
|
Module 1 Dose Schedule 9
n=67 Participants
Camonsertib Monotherapy 3 days on 4 days off Schedule, 160 mg QD
|
Module 1 Dose Schedule 10
n=30 Participants
Camonsertib Monotherapy 3 days on 4 days off Schedule, 160 mg QD, 2 weeks on 1 week off
|
Module 1 Dose Schedule 11
n=5 Participants
Camonsertib Monotherapy 3 days on 4 days off Schedule, 200 mg QD, 2 weeks on 1 week off
|
Module 3a Dose Schedule 1
n=2 Participants
Talazoparib daily, Camonsertib Day 5 -7 , 3 weeks on schedule, Talazoparib 0.5 mg QD + Camonsertib 25 mg QD
|
Module 3a Dose Schedule 2
n=3 Participants
Talazoparib daily, Camonsertib Day 5 - 7, 3 weeks on, Talazoparib 0.25 mg QD + Camonsertib 25 mg BID
|
Module 3a Dose Schedule 3
n=6 Participants
Talazoparib daily, Camonsertib Day 5 - 7, 1 week on 1 week off Schedule, Talazoparib 0.25 mg QD + Camonsertib 50 mg QD
|
Module 3a Dose Schedule 4
n=32 Participants
Talazoparib daily, Camonsertib Day 5 - 7, 1 week on 1 week off Schedule, Talazoparib 0.25 mg QD + Camonsertib 80 mg QD
|
Module 4 Dose Schedule 1
n=5 Participants
Gemcitabine 400 mg/m2 + Camonsertib 80 mg QD 3 days on 4 days off, 2 weeks on 1 week off
|
Module 4 Dose Schedule 2
n=6 Participants
Gemcitabine 600 mg/m2 + Camonsertib 80 mg QD, 3 days on 4 days off, 2 weeks on 1 week off
|
Module 4 Dose Schedule 3
n=2 Participants
Gemcitabine 800 mg/m2 + Camonsertib 80 mg QD, 3 days on 4 days off, 2 weeks on 1 week off
|
Module 4 Dose Schedule 4
n=5 Participants
Gemcitabine 1000 mg/m2 + Camonsertib 80 mg QD, 3 days on 4 days off, 2 weeks on 1 week off
|
Module 4 Dose Schedule 5
n=28 Participants
Gemcitabine 400 mg/m2 + Camonsertib 80 mg QD, 3 days on 4 days off, 1 week on 1 week off
|
Module 4 Dose Schedule 6
n=3 Participants
Gemcitabine 400 mg/m2 + Camonsertib 80 mg QD, 2 days on 5 days off, 1 week on 1 week off
|
Module 4 Dose Schedule 7
n=2 Participants
Gemcitabine 100 mg/m2 + Camonsertib 120 mg QD, 2 days on 5 days off, 2 weeks on 1 week off
|
Module 4 Dose Schedule 8
n=6 Participants
Gemcitabine 100 mg/m2 + Camonsertib 80 mg QD, 2 days on 5 days off, 2 weeks on 1 week off
|
Module 4 Dose Schedule 9
n=12 Participants
Gemcitabine 200 mg/m2 + Camonsertib 80 mg QD, 2 days on 5 days off, 2 weeks on 1 week off
|
Module 4 Dose Schedule 10
n=7 Participants
Gemcitabine 200 mg/m2 + Camonsertib 80 mg QD, 2 days on 5 days off, 1 week on 1 week off
|
Total
n=276 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Age, Customized
Age
|
57 years
n=5 Participants
|
68 years
n=7 Participants
|
59 years
n=5 Participants
|
65 years
n=4 Participants
|
61 years
n=21 Participants
|
34 years
n=8 Participants
|
64.5 years
n=8 Participants
|
64 years
n=24 Participants
|
61 years
n=42 Participants
|
68 years
n=42 Participants
|
63 years
n=42 Participants
|
45.5 years
n=42 Participants
|
57 years
n=36 Participants
|
63 years
n=36 Participants
|
57 years
n=24 Participants
|
59 years
n=135 Participants
|
60.5 years
n=136 Participants
|
64 years
n=44 Participants
|
68 years
n=667 Participants
|
62.5 years
n=15 Participants
|
55 years
n=40 Participants
|
69 years
n=40 Participants
|
57.5 years
n=41 Participants
|
62.5 years
n=600 Participants
|
55 years
n=4 Participants
|
62 years
n=4 Participants
|
|
Sex: Female, Male
Female
|
4 Participants
n=5 Participants
|
5 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
15 Participants
n=24 Participants
|
42 Participants
n=42 Participants
|
17 Participants
n=42 Participants
|
2 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
3 Participants
n=36 Participants
|
3 Participants
n=36 Participants
|
17 Participants
n=24 Participants
|
4 Participants
n=135 Participants
|
3 Participants
n=136 Participants
|
1 Participants
n=44 Participants
|
2 Participants
n=667 Participants
|
27 Participants
n=15 Participants
|
2 Participants
n=40 Participants
|
2 Participants
n=40 Participants
|
4 Participants
n=41 Participants
|
9 Participants
n=600 Participants
|
7 Participants
n=4 Participants
|
176 Participants
n=4 Participants
|
|
Sex: Female, Male
Male
|
3 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
5 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
10 Participants
n=24 Participants
|
25 Participants
n=42 Participants
|
13 Participants
n=42 Participants
|
3 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
3 Participants
n=36 Participants
|
15 Participants
n=24 Participants
|
1 Participants
n=135 Participants
|
3 Participants
n=136 Participants
|
1 Participants
n=44 Participants
|
3 Participants
n=667 Participants
|
1 Participants
n=15 Participants
|
1 Participants
n=40 Participants
|
0 Participants
n=40 Participants
|
2 Participants
n=41 Participants
|
3 Participants
n=600 Participants
|
0 Participants
n=4 Participants
|
100 Participants
n=4 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
0 Participants
n=667 Participants
|
0 Participants
n=15 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=600 Participants
|
0 Participants
n=4 Participants
|
1 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Asian
|
1 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
2 Participants
n=24 Participants
|
3 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
3 Participants
n=24 Participants
|
0 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
0 Participants
n=667 Participants
|
2 Participants
n=15 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=41 Participants
|
1 Participants
n=600 Participants
|
2 Participants
n=4 Participants
|
17 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
0 Participants
n=667 Participants
|
0 Participants
n=15 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=600 Participants
|
0 Participants
n=4 Participants
|
1 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=24 Participants
|
4 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
2 Participants
n=24 Participants
|
1 Participants
n=135 Participants
|
2 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
0 Participants
n=667 Participants
|
0 Participants
n=15 Participants
|
1 Participants
n=40 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=41 Participants
|
1 Participants
n=600 Participants
|
0 Participants
n=4 Participants
|
16 Participants
n=4 Participants
|
|
Race (NIH/OMB)
White
|
5 Participants
n=5 Participants
|
5 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
16 Participants
n=24 Participants
|
51 Participants
n=42 Participants
|
17 Participants
n=42 Participants
|
5 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
3 Participants
n=36 Participants
|
4 Participants
n=36 Participants
|
21 Participants
n=24 Participants
|
3 Participants
n=135 Participants
|
4 Participants
n=136 Participants
|
2 Participants
n=44 Participants
|
5 Participants
n=667 Participants
|
20 Participants
n=15 Participants
|
2 Participants
n=40 Participants
|
2 Participants
n=40 Participants
|
6 Participants
n=41 Participants
|
10 Participants
n=600 Participants
|
3 Participants
n=4 Participants
|
194 Participants
n=4 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
0 Participants
n=667 Participants
|
0 Participants
n=15 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=600 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
6 Participants
n=24 Participants
|
9 Participants
n=42 Participants
|
10 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
2 Participants
n=36 Participants
|
6 Participants
n=24 Participants
|
1 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
0 Participants
n=667 Participants
|
6 Participants
n=15 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=600 Participants
|
2 Participants
n=4 Participants
|
47 Participants
n=4 Participants
|
|
Eligibility Genotype
ATM
|
4 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
4 Participants
n=8 Participants
|
5 Participants
n=24 Participants
|
25 Participants
n=42 Participants
|
11 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
2 Participants
n=36 Participants
|
3 Participants
n=36 Participants
|
4 Participants
n=24 Participants
|
1 Participants
n=135 Participants
|
3 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
1 Participants
n=667 Participants
|
4 Participants
n=15 Participants
|
1 Participants
n=40 Participants
|
0 Participants
n=40 Participants
|
1 Participants
n=41 Participants
|
2 Participants
n=600 Participants
|
1 Participants
n=4 Participants
|
82 Participants
n=4 Participants
|
|
Eligibility Genotype
BRCA1
|
1 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
4 Participants
n=24 Participants
|
15 Participants
n=42 Participants
|
9 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
1 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
5 Participants
n=24 Participants
|
2 Participants
n=135 Participants
|
2 Participants
n=136 Participants
|
1 Participants
n=44 Participants
|
0 Participants
n=667 Participants
|
14 Participants
n=15 Participants
|
1 Participants
n=40 Participants
|
1 Participants
n=40 Participants
|
2 Participants
n=41 Participants
|
5 Participants
n=600 Participants
|
2 Participants
n=4 Participants
|
69 Participants
n=4 Participants
|
|
Eligibility Genotype
BRCA2
|
0 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
4 Participants
n=24 Participants
|
8 Participants
n=42 Participants
|
3 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
1 Participants
n=36 Participants
|
15 Participants
n=24 Participants
|
1 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
3 Participants
n=667 Participants
|
5 Participants
n=15 Participants
|
1 Participants
n=40 Participants
|
1 Participants
n=40 Participants
|
2 Participants
n=41 Participants
|
4 Participants
n=600 Participants
|
3 Participants
n=4 Participants
|
54 Participants
n=4 Participants
|
|
Eligibility Genotype
CDK12
|
0 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
3 Participants
n=24 Participants
|
3 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
1 Participants
n=36 Participants
|
1 Participants
n=24 Participants
|
0 Participants
n=135 Participants
|
1 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
0 Participants
n=667 Participants
|
1 Participants
n=15 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=600 Participants
|
0 Participants
n=4 Participants
|
14 Participants
n=4 Participants
|
|
Eligibility Genotype
CHEK2
|
1 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
2 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
0 Participants
n=667 Participants
|
0 Participants
n=15 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=600 Participants
|
0 Participants
n=4 Participants
|
4 Participants
n=4 Participants
|
|
Eligibility Genotype
PALB2
|
1 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
3 Participants
n=24 Participants
|
2 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
2 Participants
n=24 Participants
|
1 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
0 Participants
n=667 Participants
|
1 Participants
n=15 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=40 Participants
|
1 Participants
n=41 Participants
|
0 Participants
n=600 Participants
|
0 Participants
n=4 Participants
|
11 Participants
n=4 Participants
|
|
Eligibility Genotype
RAD51B
|
0 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
2 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
1 Participants
n=24 Participants
|
0 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
1 Participants
n=667 Participants
|
0 Participants
n=15 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=600 Participants
|
0 Participants
n=4 Participants
|
5 Participants
n=4 Participants
|
|
Eligibility Genotype
RNAseH2
|
0 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
2 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
2 Participants
n=24 Participants
|
0 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
0 Participants
n=667 Participants
|
0 Participants
n=15 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=600 Participants
|
0 Participants
n=4 Participants
|
8 Participants
n=4 Participants
|
|
Eligibility Genotype
SETD2
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
3 Participants
n=24 Participants
|
6 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
1 Participants
n=36 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
1 Participants
n=44 Participants
|
0 Participants
n=667 Participants
|
1 Participants
n=15 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=600 Participants
|
0 Participants
n=4 Participants
|
14 Participants
n=4 Participants
|
|
Eligibility Genotype
NBN
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
3 Participants
n=42 Participants
|
2 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
1 Participants
n=24 Participants
|
0 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
0 Participants
n=667 Participants
|
0 Participants
n=15 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=600 Participants
|
0 Participants
n=4 Participants
|
6 Participants
n=4 Participants
|
|
Eligibility Genotype
IDH1
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
1 Participants
n=24 Participants
|
0 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
0 Participants
n=667 Participants
|
0 Participants
n=15 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=600 Participants
|
0 Participants
n=4 Participants
|
1 Participants
n=4 Participants
|
|
Eligibility Genotype
MRE11A
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
0 Participants
n=667 Participants
|
0 Participants
n=15 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=41 Participants
|
1 Participants
n=600 Participants
|
0 Participants
n=4 Participants
|
1 Participants
n=4 Participants
|
|
Eligibility Genotype
RAD50
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
0 Participants
n=667 Participants
|
1 Participants
n=15 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=600 Participants
|
1 Participants
n=4 Participants
|
2 Participants
n=4 Participants
|
|
Eligibility Genotype
RAD51C
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=24 Participants
|
1 Participants
n=42 Participants
|
2 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
0 Participants
n=667 Participants
|
1 Participants
n=15 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=600 Participants
|
0 Participants
n=4 Participants
|
5 Participants
n=4 Participants
|
PRIMARY outcome
Timeframe: Start of treatment to 30 days post last dose, up to 1 yearTreatment-emergent adverse events (TEAEs) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. AEs are considered related to treatment if the relationship to camonsertib or the other combination drug (in the study regimen) is "Related" (include unknown relationship) as indicated on the AE eCRF page based on investigator's assessment.
Outcome measures
| Measure |
Cam<=80 5/2
n=7 Participants
Module 1 Dose level 1: Camonsertib 5 days on 2 days off Schedule \<=80 mg/day
|
Cam100 5/2
n=8 Participants
Module 1 Dose Schedule 2:Camonsertib Monotherapy 5 days on 2 days off Schedule, 100 mg QD
|
Cam120 5/2
n=6 Participants
Module 1 Dose Schedule 3: Camonsertib Monotherapy 5 days on 2 days off Schedule, 120 mg QD
|
Cam160 5/2
n=3 Participants
Module 1 Dose Schedule 4: Camonsertib Monotherapy 5 days on 2 days off Schedule, 160 mg QD
|
Cam80BID 5/2
n=1 Participants
Module 1 Dose Schedule 5: Camonsertib Monotherapy 5 days on 2 days off Schedule, 80 mg BID
|
Cam40BID 3/4
n=1 Participants
Module 1 Dose Schedule 6: Camonsertib Monotherapy 3 days on 4 days off Schedule, 40 mg BID
|
Cam60BID 3/4
n=4 Participants
Module 1 Dose Schedule 7: Camonsertib Monotherapy 3 days on 4 days off Schedule, 60 mg BID
|
Cam120 3/4
n=25 Participants
Module 1 Dose Schedule 8: Camonsertib Monotherapy 3 days on 4 days off Schedule, 120 mg QD
|
Cam160 3/4
n=67 Participants
Module 1 Dose Schedule 9: Camonsertib Monotherapy 3 days on 4 days off Schedule, 160 mg QD
|
Cam160 2/1w
n=30 Participants
Module 1 Dose Schedule 10: Camonsertib Monotherapy 3 days on 4 days off Schedule, 160 mg QD, 2 weeks on 1 week off
|
Cam200 2/1w
n=5 Participants
Module 1 Dose Schedule 11: Camonsertib Monotherapy 3 days on 4 days off Schedule, 200 mg QD, 2 weeks on 1 week off
|
Tala0.5+Cam25
n=2 Participants
Module 3a Dose Schedule 1: Talazoparib daily, Camonsertib Day 5 -7 , 3 weeks on schedule, 0.5mg QD Talazoparib + 25mg BID Camonsertib
|
Tala0.25+Cam25
n=3 Participants
Module 3a Dose Schedule 2: Talazoparib daily, Camonsertib Day 5 - 7, 3 weeks on: 0.25mg QD Talazoparib + 25mg BID Camonsertib
|
Tala0.25+Cam50
n=6 Participants
Module 3a Dose Schedule 3: Talazoparib daily, Camonsertib Day 5 - 7, 1 week on 1 week off Schedule, 0.25mg QD Talazoparib + 50mg QD Camonsertib
|
Tala0.25+Cam80
n=32 Participants
Module 3a Dose Schedule 4: Talazoparib daily, Camonsertib Day 5 - 7, 1 week on 1 week off Schedule, 0.25mg QD Talazoparib + 80mg QD Camonsertib
|
Gem400+Cam80 2/1
n=5 Participants
Module 4 Dose Schedule 1: Gemcitabine 400 mg/m2 + Camonsertib 80 mg QD 3 days on 4 days off, 2 weeks on 1 week off
|
Gem600+Cam80
n=6 Participants
Module 4 Dose Schedule 2: Gemcitabine 600 mg/m2 + Camonsertib 80 mg QD, 3 days on 4 days off, 2 weeks on 1 week off
|
Gem800+Cam80
n=2 Participants
Module 4 Dose Schedule 3: Gemcitabine 800 mg/m2 + Camonsertib 80 mg QD, 3 days on 4 days off, 2 weeks on 1 weeks off
|
Gem1000+Cam80
n=5 Participants
Module 4 Dose Schedule 4: Gemcitabine 1000 mg/m2 + Camonsertib 80 mg QD, 3 days on 4 days off, 2 weeks on 1 week off
|
Gem400+Cam80 1/1w
n=28 Participants
Module 4 Dose Schedule 5: Gemcitabine 400 mg/m2 + Camonsertib 80 mg QD, 3 days on 4 days off, 1 week on 1 week off
|
Gem400+Cam80 2/5
n=3 Participants
Module 4 Dose Schedule 6: Gemcitabine 400 mg/m2 + Camonsertib 80mg QD, 2 days on 5 days off, 1 week on 1 week off
|
Gem100+Cam120
n=2 Participants
Module 4 Dose Schedule 7: Gemcitabine 100mg/m2 + Camonsertib 120 mg QD, 2 days on 5 days off, 2 weeks on 1 week off
|
Gem100+Cam80mg
n=6 Participants
Module 4 Dose Schedule 8: Gemcitabine 100 mg/m2 + Camonsertib 80 mg QD, 2 days on 5 days off, 2 weeks on 1 week off
|
Gem200+Cam80 2/1w
n=12 Participants
Module 4 Dose Schedule 9: Gemcitabine 200 mg/m2 + Camonsertib 80 mg QD, 2 days on 5 days off, 2 weeks on 1 week off
|
Gem200+Cam80 1/1w
n=7 Participants
Module 4 Dose Schedule 10: Gemcitabine 200 mg/m2 + Camonsertib 80 mg QD, 2 days on 5 days off, 1 week on 1 week off
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Frequency of Treatment-Related Adverse Event of CTCAE Grade 3 and Above
|
2 Participants
|
5 Participants
|
6 Participants
|
2 Participants
|
1 Participants
|
1 Participants
|
3 Participants
|
8 Participants
|
32 Participants
|
8 Participants
|
3 Participants
|
2 Participants
|
3 Participants
|
3 Participants
|
19 Participants
|
5 Participants
|
5 Participants
|
1 Participants
|
5 Participants
|
19 Participants
|
1 Participants
|
1 Participants
|
6 Participants
|
9 Participants
|
4 Participants
|
PRIMARY outcome
Timeframe: Either 21 days or 28 days (1 cycle) from the initiation of the study treatment.Population: Rate of DLT among DLT-evaluable population. DLT-evaluable population consists of patients who: * Experience a DLT event or * Received at least 80% of planned total doses of RP-3500 during Cycle 1 (Module 1), both RP-3500 and talazoparib (Module 3), or 80% of RP-3500 and 100% of gemcitabine (Module 4), complete all required safety evaluations, and are observed through the end of Cycle 1
Toxicity were assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. A toxicity was considered dose-limiting if it occurred during the first cycle and was deemed at least possibly related to study treatment. If multiple toxicities occurred, the most severe toxicity was used in the assessment. The DLT Evaluable population consists of patients who received at least 80% of planned total doses of camonsertib , 80% of planned total doses of camonsertib and talazoparib, or 80% of planned total doses of camonsertib and 100% of gemcitabine; complete all required safety evaluations and are observed through the end of Cycle 1; or patients who experience a DLT qualifying event in the first cycle of treatment.
Outcome measures
| Measure |
Cam<=80 5/2
n=6 Participants
Module 1 Dose level 1: Camonsertib 5 days on 2 days off Schedule \<=80 mg/day
|
Cam100 5/2
n=4 Participants
Module 1 Dose Schedule 2:Camonsertib Monotherapy 5 days on 2 days off Schedule, 100 mg QD
|
Cam120 5/2
n=4 Participants
Module 1 Dose Schedule 3: Camonsertib Monotherapy 5 days on 2 days off Schedule, 120 mg QD
|
Cam160 5/2
n=3 Participants
Module 1 Dose Schedule 4: Camonsertib Monotherapy 5 days on 2 days off Schedule, 160 mg QD
|
Cam80BID 5/2
Module 1 Dose Schedule 5: Camonsertib Monotherapy 5 days on 2 days off Schedule, 80 mg BID
|
Cam40BID 3/4
Module 1 Dose Schedule 6: Camonsertib Monotherapy 3 days on 4 days off Schedule, 40 mg BID
|
Cam60BID 3/4
n=3 Participants
Module 1 Dose Schedule 7: Camonsertib Monotherapy 3 days on 4 days off Schedule, 60 mg BID
|
Cam120 3/4
n=16 Participants
Module 1 Dose Schedule 8: Camonsertib Monotherapy 3 days on 4 days off Schedule, 120 mg QD
|
Cam160 3/4
n=38 Participants
Module 1 Dose Schedule 9: Camonsertib Monotherapy 3 days on 4 days off Schedule, 160 mg QD
|
Cam160 2/1w
n=26 Participants
Module 1 Dose Schedule 10: Camonsertib Monotherapy 3 days on 4 days off Schedule, 160 mg QD, 2 weeks on 1 week off
|
Cam200 2/1w
n=5 Participants
Module 1 Dose Schedule 11: Camonsertib Monotherapy 3 days on 4 days off Schedule, 200 mg QD, 2 weeks on 1 week off
|
Tala0.5+Cam25
n=2 Participants
Module 3a Dose Schedule 1: Talazoparib daily, Camonsertib Day 5 -7 , 3 weeks on schedule, 0.5mg QD Talazoparib + 25mg BID Camonsertib
|
Tala0.25+Cam25
n=3 Participants
Module 3a Dose Schedule 2: Talazoparib daily, Camonsertib Day 5 - 7, 3 weeks on: 0.25mg QD Talazoparib + 25mg BID Camonsertib
|
Tala0.25+Cam50
n=6 Participants
Module 3a Dose Schedule 3: Talazoparib daily, Camonsertib Day 5 - 7, 1 week on 1 week off Schedule, 0.25mg QD Talazoparib + 50mg QD Camonsertib
|
Tala0.25+Cam80
n=25 Participants
Module 3a Dose Schedule 4: Talazoparib daily, Camonsertib Day 5 - 7, 1 week on 1 week off Schedule, 0.25mg QD Talazoparib + 80mg QD Camonsertib
|
Gem400+Cam80 2/1
n=5 Participants
Module 4 Dose Schedule 1: Gemcitabine 400 mg/m2 + Camonsertib 80 mg QD 3 days on 4 days off, 2 weeks on 1 week off
|
Gem600+Cam80
n=2 Participants
Module 4 Dose Schedule 2: Gemcitabine 600 mg/m2 + Camonsertib 80 mg QD, 3 days on 4 days off, 2 weeks on 1 week off
|
Gem800+Cam80
Module 4 Dose Schedule 3: Gemcitabine 800 mg/m2 + Camonsertib 80 mg QD, 3 days on 4 days off, 2 weeks on 1 weeks off
|
Gem1000+Cam80
n=3 Participants
Module 4 Dose Schedule 4: Gemcitabine 1000 mg/m2 + Camonsertib 80 mg QD, 3 days on 4 days off, 2 weeks on 1 week off
|
Gem400+Cam80 1/1w
n=26 Participants
Module 4 Dose Schedule 5: Gemcitabine 400 mg/m2 + Camonsertib 80 mg QD, 3 days on 4 days off, 1 week on 1 week off
|
Gem400+Cam80 2/5
n=3 Participants
Module 4 Dose Schedule 6: Gemcitabine 400 mg/m2 + Camonsertib 80mg QD, 2 days on 5 days off, 1 week on 1 week off
|
Gem100+Cam120
n=2 Participants
Module 4 Dose Schedule 7: Gemcitabine 100mg/m2 + Camonsertib 120 mg QD, 2 days on 5 days off, 2 weeks on 1 week off
|
Gem100+Cam80mg
n=6 Participants
Module 4 Dose Schedule 8: Gemcitabine 100 mg/m2 + Camonsertib 80 mg QD, 2 days on 5 days off, 2 weeks on 1 week off
|
Gem200+Cam80 2/1w
n=9 Participants
Module 4 Dose Schedule 9: Gemcitabine 200 mg/m2 + Camonsertib 80 mg QD, 2 days on 5 days off, 2 weeks on 1 week off
|
Gem200+Cam80 1/1w
n=7 Participants
Module 4 Dose Schedule 10: Gemcitabine 200 mg/m2 + Camonsertib 80 mg QD, 2 days on 5 days off, 1 week on 1 week off
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Frequency of Dose Limiting Toxicity (DLT)
|
0 Participants
|
2 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
3 Participants
|
2 Participants
|
1 Participants
|
2 Participants
|
1 Participants
|
0 Participants
|
6 Participants
|
5 Participants
|
1 Participants
|
0 Participants
|
2 Participants
|
7 Participants
|
2 Participants
|
1 Participants
|
2 Participants
|
3 Participants
|
0 Participants
|
Adverse Events
Cam<=80 5/2
Serious events: 1 serious events
Other events: 6 other events
Deaths: 4 deaths
Cam100 5/2
Serious events: 4 serious events
Other events: 8 other events
Deaths: 7 deaths
Cam120 5/2
Serious events: 3 serious events
Other events: 6 other events
Deaths: 3 deaths
Cam160 5/2
Serious events: 0 serious events
Other events: 3 other events
Deaths: 2 deaths
Cam80BID 5/2
Serious events: 0 serious events
Other events: 1 other events
Deaths: 1 deaths
Cam40BID 3/4
Serious events: 1 serious events
Other events: 1 other events
Deaths: 1 deaths
Cam60BID 3/4
Serious events: 1 serious events
Other events: 4 other events
Deaths: 3 deaths
Cam120 3/4
Serious events: 5 serious events
Other events: 23 other events
Deaths: 10 deaths
Cam160 3/4
Serious events: 20 serious events
Other events: 65 other events
Deaths: 41 deaths
Cam160 2/1w
Serious events: 9 serious events
Other events: 29 other events
Deaths: 16 deaths
Cam200 2/1w
Serious events: 2 serious events
Other events: 5 other events
Deaths: 3 deaths
Tala0.5+Cam25
Serious events: 1 serious events
Other events: 2 other events
Deaths: 1 deaths
Tala0.25+Cam25
Serious events: 1 serious events
Other events: 3 other events
Deaths: 1 deaths
Tala0.25+Cam50
Serious events: 1 serious events
Other events: 6 other events
Deaths: 3 deaths
Tala0.25+Cam80
Serious events: 11 serious events
Other events: 32 other events
Deaths: 18 deaths
Gem400+Cam80 2/1
Serious events: 2 serious events
Other events: 5 other events
Deaths: 3 deaths
Gem600+Cam80
Serious events: 4 serious events
Other events: 6 other events
Deaths: 2 deaths
Gem800+Cam80
Serious events: 1 serious events
Other events: 2 other events
Deaths: 1 deaths
Gem1000+Cam80
Serious events: 2 serious events
Other events: 5 other events
Deaths: 4 deaths
Gem400+Cam80 1/1w
Serious events: 10 serious events
Other events: 28 other events
Deaths: 17 deaths
Gem400+Cam80 2/5
Serious events: 2 serious events
Other events: 3 other events
Deaths: 1 deaths
Gem100+Cam120
Serious events: 1 serious events
Other events: 2 other events
Deaths: 0 deaths
Gem100+Cam80mg
Serious events: 3 serious events
Other events: 6 other events
Deaths: 3 deaths
Gem200+Cam80 2/1w
Serious events: 5 serious events
Other events: 12 other events
Deaths: 5 deaths
Gem200+Cam80 1/1w
Serious events: 2 serious events
Other events: 7 other events
Deaths: 4 deaths
Serious adverse events
| Measure |
Cam<=80 5/2
n=7 participants at risk
Module 1 Dose level 1: Camonsertib 5 days on 2 days off Schedule \<=80 mg/day
|
Cam100 5/2
n=8 participants at risk
Module 1 Dose Schedule 2:Camonsertib Monotherapy 5 days on 2 days off Schedule, 100 mg QD
|
Cam120 5/2
n=6 participants at risk
Module 1 Dose Schedule 3: Camonsertib Monotherapy 5 days on 2 days off Schedule, 120 mg QD
|
Cam160 5/2
n=3 participants at risk
Module 1 Dose Schedule 4: Camonsertib Monotherapy 5 days on 2 days off Schedule, 160 mg QD
|
Cam80BID 5/2
n=1 participants at risk
Module 1 Dose Schedule 5: Camonsertib Monotherapy 5 days on 2 days off Schedule, 80 mg BID
|
Cam40BID 3/4
n=1 participants at risk
Module 1 Dose Schedule 6: Camonsertib Monotherapy 3 days on 4 days off Schedule, 40 mg BID
|
Cam60BID 3/4
n=4 participants at risk
Module 1 Dose Schedule 7: Camonsertib Monotherapy 3 days on 4 days off Schedule, 60 mg BID
|
Cam120 3/4
n=25 participants at risk
Module 1 Dose Schedule 8: Camonsertib Monotherapy 3 days on 4 days off Schedule, 120 mg QD
|
Cam160 3/4
n=67 participants at risk
Module 1 Dose Schedule 9: Camonsertib Monotherapy 3 days on 4 days off Schedule, 160 mg QD
|
Cam160 2/1w
n=30 participants at risk
Module 1 Dose Schedule 10: Camonsertib Monotherapy 3 days on 4 days off Schedule, 160 mg QD, 2 weeks on 1 week off
|
Cam200 2/1w
n=5 participants at risk
Module 1 Dose Schedule 11: Camonsertib Monotherapy 3 days on 4 days off Schedule, 200 mg QD, 2 weeks on 1 week off
|
Tala0.5+Cam25
n=2 participants at risk
Module 3a Dose Schedule 1: Talazoparib daily, Camonsertib Day 5 -7 , 3 weeks on schedule, 0.5mg QD Talazoparib + 25mg BID Camonsertib
|
Tala0.25+Cam25
n=3 participants at risk
Module 3a Dose Schedule 2: Talazoparib daily, Camonsertib Day 5 - 7, 3 weeks on: 0.25mg QD Talazoparib + 25mg BID Camonsertib
|
Tala0.25+Cam50
n=6 participants at risk
Module 3a Dose Schedule 3: Talazoparib daily, Camonsertib Day 5 - 7, 1 week on 1 week off Schedule, 0.25mg QD Talazoparib + 50mg QD Camonsertib
|
Tala0.25+Cam80
n=32 participants at risk
Module 3a Dose Schedule 4: Talazoparib daily, Camonsertib Day 5 - 7, 1 week on 1 week off Schedule, 0.25mg QD Talazoparib + 80mg QD Camonsertib
|
Gem400+Cam80 2/1
n=5 participants at risk
Module 4 Dose Schedule 1: Gemcitabine 400 mg/m2 + Camonsertib 80 mg QD 3 days on 4 days off, 2 weeks on 1 week off
|
Gem600+Cam80
n=6 participants at risk
Module 4 Dose Schedule 2: Gemcitabine 600 mg/m2 + Camonsertib 80 mg QD, 3 days on 4 days off, 2 weeks on 1 week off
|
Gem800+Cam80
n=2 participants at risk
Module 4 Dose Schedule 3: Gemcitabine 800 mg/m2 + Camonsertib 80 mg QD, 3 days on 4 days off, 2 weeks on 1 weeks off
|
Gem1000+Cam80
n=5 participants at risk
Module 4 Dose Schedule 4: Gemcitabine 1000 mg/m2 + Camonsertib 80 mg QD, 3 days on 4 days off, 2 weeks on 1 week off
|
Gem400+Cam80 1/1w
n=28 participants at risk
Module 4 Dose Schedule 5: Gemcitabine 400 mg/m2 + Camonsertib 80 mg QD, 3 days on 4 days off, 1 week on 1 week off
|
Gem400+Cam80 2/5
n=3 participants at risk
Module 4 Dose Schedule 6: Gemcitabine 400 mg/m2 + Camonsertib 80mg QD, 2 days on 5 days off, 1 week on 1 week off
|
Gem100+Cam120
n=2 participants at risk
Module 4 Dose Schedule 7: Gemcitabine 100mg/m2 + Camonsertib 120 mg QD, 2 days on 5 days off, 2 weeks on 1 week off
|
Gem100+Cam80mg
n=6 participants at risk
Module 4 Dose Schedule 8: Gemcitabine 100 mg/m2 + Camonsertib 80 mg QD, 2 days on 5 days off, 2 weeks on 1 week off
|
Gem200+Cam80 2/1w
n=12 participants at risk
Module 4 Dose Schedule 9: Gemcitabine 200 mg/m2 + Camonsertib 80 mg QD, 2 days on 5 days off, 2 weeks on 1 week off
|
Gem200+Cam80 1/1w
n=7 participants at risk
Module 4 Dose Schedule 10: Gemcitabine 200 mg/m2 + Camonsertib 80 mg QD, 2 days on 5 days off, 1 week on 1 week off
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Nervous system disorders
Dizziness
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.5%
3/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.0%
4/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Blood and lymphatic system disorders
Neutrophil count decreased/ Neutropenia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.2%
2/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Blood and lymphatic system disorders
Platelet count decreased/ Thrombocytopenia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.0%
2/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Blood and lymphatic system disorders
WBC count decreased/ Leukopenia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Cardiac disorders
Cardiac failure
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Cardiac disorders
Pericardial effusion
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Endocrine disorders
Adrenal insufficiency
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.2%
2/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Ascites
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Colitis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Duodenal stenosis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Enterovesical fistula
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Gastrointestinal haemorrhage
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Haematochezia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Ileus
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Intestinal fistula
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Intestinal obstruction
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
7.1%
2/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Large intestinal obstruction
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Obstruction gastric
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Small intestinal obstruction
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.0%
2/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.0%
2/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Small intestinal perforation
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Upper gastrointestinal haemorrhage
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
General disorders and administration site conditions
Asthenia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
General disorders and administration site conditions
Fatigue
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
General disorders and administration site conditions
Gait disturbance
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
General disorders and administration site conditions
Non-cardiac chest pain
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
General disorders and administration site conditions
Oedema peripheral
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
1/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
General disorders and administration site conditions
Pyrexia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
3/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
7.1%
2/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Hepatobiliary disorders
Biliary obstruction
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.0%
2/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Hepatobiliary disorders
Cholangitis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Hepatobiliary disorders
Hyperbilirubinaemia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Immune system disorders
Hypersensitivity
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Abdominal infection
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Abdominal wall abscess
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Arthritis infective
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Bacteraemia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
COVID-19 pneumonia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Cellulitis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Diverticulitis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Erysipelas
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Herpes zoster
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Infection
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Kidney infection
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Lower respiratory tract infection
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Neutropenic infection
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Neutropenic sepsis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.0%
2/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Sepsis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Skin infection
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Injury, poisoning and procedural complications
Arterial injury
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Injury, poisoning and procedural complications
Hip fracture
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Investigations
Aspartate aminotransferase increased
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Metabolism and nutrition disorders
Failure to thrive
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
2/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peritumoural oedema
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour haemorrhage
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour pain
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Nervous system disorders
Cerebrovascular accident
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Nervous system disorders
Headache
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Nervous system disorders
Lethargy
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Nervous system disorders
Seizure
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Product issues
Device dislocation
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Product issues
Device occlusion
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Psychiatric disorders
Hallucination
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Renal and urinary disorders
Nephrolithiasis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Renal and urinary disorders
Ureteric obstruction
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Renal and urinary disorders
Urinary tract obstruction
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Respiratory, thoracic and mediastinal disorders
Aspiration
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
1/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.5%
3/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Vascular disorders
Embolism
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Vascular disorders
Hypotension
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
Other adverse events
| Measure |
Cam<=80 5/2
n=7 participants at risk
Module 1 Dose level 1: Camonsertib 5 days on 2 days off Schedule \<=80 mg/day
|
Cam100 5/2
n=8 participants at risk
Module 1 Dose Schedule 2:Camonsertib Monotherapy 5 days on 2 days off Schedule, 100 mg QD
|
Cam120 5/2
n=6 participants at risk
Module 1 Dose Schedule 3: Camonsertib Monotherapy 5 days on 2 days off Schedule, 120 mg QD
|
Cam160 5/2
n=3 participants at risk
Module 1 Dose Schedule 4: Camonsertib Monotherapy 5 days on 2 days off Schedule, 160 mg QD
|
Cam80BID 5/2
n=1 participants at risk
Module 1 Dose Schedule 5: Camonsertib Monotherapy 5 days on 2 days off Schedule, 80 mg BID
|
Cam40BID 3/4
n=1 participants at risk
Module 1 Dose Schedule 6: Camonsertib Monotherapy 3 days on 4 days off Schedule, 40 mg BID
|
Cam60BID 3/4
n=4 participants at risk
Module 1 Dose Schedule 7: Camonsertib Monotherapy 3 days on 4 days off Schedule, 60 mg BID
|
Cam120 3/4
n=25 participants at risk
Module 1 Dose Schedule 8: Camonsertib Monotherapy 3 days on 4 days off Schedule, 120 mg QD
|
Cam160 3/4
n=67 participants at risk
Module 1 Dose Schedule 9: Camonsertib Monotherapy 3 days on 4 days off Schedule, 160 mg QD
|
Cam160 2/1w
n=30 participants at risk
Module 1 Dose Schedule 10: Camonsertib Monotherapy 3 days on 4 days off Schedule, 160 mg QD, 2 weeks on 1 week off
|
Cam200 2/1w
n=5 participants at risk
Module 1 Dose Schedule 11: Camonsertib Monotherapy 3 days on 4 days off Schedule, 200 mg QD, 2 weeks on 1 week off
|
Tala0.5+Cam25
n=2 participants at risk
Module 3a Dose Schedule 1: Talazoparib daily, Camonsertib Day 5 -7 , 3 weeks on schedule, 0.5mg QD Talazoparib + 25mg BID Camonsertib
|
Tala0.25+Cam25
n=3 participants at risk
Module 3a Dose Schedule 2: Talazoparib daily, Camonsertib Day 5 - 7, 3 weeks on: 0.25mg QD Talazoparib + 25mg BID Camonsertib
|
Tala0.25+Cam50
n=6 participants at risk
Module 3a Dose Schedule 3: Talazoparib daily, Camonsertib Day 5 - 7, 1 week on 1 week off Schedule, 0.25mg QD Talazoparib + 50mg QD Camonsertib
|
Tala0.25+Cam80
n=32 participants at risk
Module 3a Dose Schedule 4: Talazoparib daily, Camonsertib Day 5 - 7, 1 week on 1 week off Schedule, 0.25mg QD Talazoparib + 80mg QD Camonsertib
|
Gem400+Cam80 2/1
n=5 participants at risk
Module 4 Dose Schedule 1: Gemcitabine 400 mg/m2 + Camonsertib 80 mg QD 3 days on 4 days off, 2 weeks on 1 week off
|
Gem600+Cam80
n=6 participants at risk
Module 4 Dose Schedule 2: Gemcitabine 600 mg/m2 + Camonsertib 80 mg QD, 3 days on 4 days off, 2 weeks on 1 week off
|
Gem800+Cam80
n=2 participants at risk
Module 4 Dose Schedule 3: Gemcitabine 800 mg/m2 + Camonsertib 80 mg QD, 3 days on 4 days off, 2 weeks on 1 weeks off
|
Gem1000+Cam80
n=5 participants at risk
Module 4 Dose Schedule 4: Gemcitabine 1000 mg/m2 + Camonsertib 80 mg QD, 3 days on 4 days off, 2 weeks on 1 week off
|
Gem400+Cam80 1/1w
n=28 participants at risk
Module 4 Dose Schedule 5: Gemcitabine 400 mg/m2 + Camonsertib 80 mg QD, 3 days on 4 days off, 1 week on 1 week off
|
Gem400+Cam80 2/5
n=3 participants at risk
Module 4 Dose Schedule 6: Gemcitabine 400 mg/m2 + Camonsertib 80mg QD, 2 days on 5 days off, 1 week on 1 week off
|
Gem100+Cam120
n=2 participants at risk
Module 4 Dose Schedule 7: Gemcitabine 100mg/m2 + Camonsertib 120 mg QD, 2 days on 5 days off, 2 weeks on 1 week off
|
Gem100+Cam80mg
n=6 participants at risk
Module 4 Dose Schedule 8: Gemcitabine 100 mg/m2 + Camonsertib 80 mg QD, 2 days on 5 days off, 2 weeks on 1 week off
|
Gem200+Cam80 2/1w
n=12 participants at risk
Module 4 Dose Schedule 9: Gemcitabine 200 mg/m2 + Camonsertib 80 mg QD, 2 days on 5 days off, 2 weeks on 1 week off
|
Gem200+Cam80 1/1w
n=7 participants at risk
Module 4 Dose Schedule 10: Gemcitabine 200 mg/m2 + Camonsertib 80 mg QD, 2 days on 5 days off, 1 week on 1 week off
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gastrointestinal disorders
Mucous stools
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Nausea
|
28.6%
2/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
2/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
2/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
66.7%
2/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
10/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
26.9%
18/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
23.3%
7/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
2/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
37.5%
12/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
80.0%
4/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
2/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
60.0%
3/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
71.4%
20/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
58.3%
7/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
28.6%
2/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Cardiac disorders
Tachycardia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Blood and lymphatic system disorders
Anaemia
|
42.9%
3/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
8/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
6/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
3/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
1/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
1/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
75.0%
3/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
68.0%
17/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
71.6%
48/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
60.0%
18/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
5/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
2/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
3/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
2/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
75.0%
24/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
60.0%
3/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
66.7%
4/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
60.0%
3/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
64.3%
18/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
66.7%
2/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
83.3%
5/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
6/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
42.9%
3/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Blood and lymphatic system disorders
Lymph node pain
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Blood and lymphatic system disorders
Lymphopenia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Blood and lymphatic system disorders
Monocytopenia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Blood and lymphatic system disorders
Neutrophil count decreased/ Neutropenia
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
4/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
24.0%
6/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
35.8%
24/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
26.7%
8/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
2/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
3/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
65.6%
21/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
80.0%
4/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
83.3%
5/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
80.0%
4/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
57.1%
16/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
83.3%
5/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
58.3%
7/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
71.4%
5/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Blood and lymphatic system disorders
Platelet count decreased/ Thrombocytopenia
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
62.5%
5/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
1/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
1/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
5/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
19.4%
13/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
10/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
2/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
3/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
43.8%
14/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
2/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
80.0%
4/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
7/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
66.7%
2/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
66.7%
4/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
41.7%
5/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
28.6%
2/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Blood and lymphatic system disorders
WBC count decreased/ Leukopenia
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.0%
4/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
10.4%
7/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
10.0%
3/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
15.6%
5/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
60.0%
3/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
32.1%
9/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
3/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
4/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
28.6%
2/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Cardiac disorders
Cardiac failure
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Cardiac disorders
Palpitations
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.0%
2/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.0%
2/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
9.4%
3/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
10.7%
3/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Cardiac disorders
Sinus bradycardia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Cardiac disorders
Sinus tachycardia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
2/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
2/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Ear and labyrinth disorders
Ear pain
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Ear and labyrinth disorders
Hypoacusis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Ear and labyrinth disorders
Otorrhoea
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Ear and labyrinth disorders
Tinnitus
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.2%
2/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Endocrine disorders
Adrenal insufficiency
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Endocrine disorders
Hypothyroidism
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Eye disorders
Diplopia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Eye disorders
Dry eye
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.2%
2/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Eye disorders
Eye haemorrhage
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Eye disorders
Eye irritation
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Eye disorders
Eye pain
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Eye disorders
Ocular hyperaemia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Eye disorders
Vision blurred
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Eye disorders
Visual impairment
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Eye disorders
Vitreous floaters
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Abdominal discomfort
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
2/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.0%
2/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.2%
2/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Abdominal pain
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.0%
2/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
9.0%
6/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
10/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
60.0%
3/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
2/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
32.1%
9/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
3/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Abdominal pain lower
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
10.7%
3/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
2/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Anal incontinence
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Anal inflammation
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Anal pruritus
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Anorectal discomfort
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Aphthous ulcer
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.2%
2/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Ascites
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Cheilitis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Colonic fistula
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Constipation
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
3/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.0%
4/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.9%
14/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
6/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.2%
2/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
28.6%
8/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
28.6%
2/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
2/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
1/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
24.0%
6/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
23.9%
16/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
30.0%
9/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
2/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
28.1%
9/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
2/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
39.3%
11/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
2/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
2/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
42.9%
3/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Dry mouth
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.0%
2/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.0%
2/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
9.4%
3/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
7.1%
2/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.0%
3/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.5%
3/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
7.1%
2/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Glossodynia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.7%
2/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
28.6%
2/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Eructation
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Faeces discoloured
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Flatulence
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Gastritis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.0%
2/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.5%
3/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
10.0%
3/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Haemorrhoids
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Ileus
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Lip pain
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Melaena
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Oral dysaesthesia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Oral pain
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Proctalgia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Rectal haemorrhage
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
General disorders and administration site conditions
Fatigue
|
28.6%
2/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
2/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
66.7%
4/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
66.7%
2/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
1/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
75.0%
3/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
10/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
47.8%
32/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
36.7%
11/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
66.7%
4/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
53.1%
17/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
66.7%
4/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
60.0%
3/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
75.0%
21/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
66.7%
2/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
66.7%
4/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
91.7%
11/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
42.9%
3/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Hepatobiliary disorders
Cholestasis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Salivary hypersecretion
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
General disorders and administration site conditions
Feeling jittery
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Small intestinal obstruction
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Stomatitis
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.0%
3/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.5%
3/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.2%
2/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
60.0%
3/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
53.6%
15/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
2/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Toothache
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Vomiting
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
2/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
1/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
5/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
19.4%
13/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
23.3%
7/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
2/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
3/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
31.2%
10/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
2/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
60.0%
3/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
46.4%
13/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
3/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
6/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
General disorders and administration site conditions
Asthenia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
General disorders and administration site conditions
Axillary pain
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
General disorders and administration site conditions
Catheter site erosion
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Ear infection
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Eye infection
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
General disorders and administration site conditions
Catheter site pruritus
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
COVID-19
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
9.0%
6/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.7%
2/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
15.6%
5/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
2/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
General disorders and administration site conditions
Catheter site rash
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Cystitis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.2%
2/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
General disorders and administration site conditions
Chest discomfort
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
General disorders and administration site conditions
Chest pain
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
General disorders and administration site conditions
Chills
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.0%
2/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
9.4%
3/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
2/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
17.9%
5/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
2/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
General disorders and administration site conditions
Face oedema
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
General disorders and administration site conditions
Generalised oedema
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
General disorders and administration site conditions
Hot flush
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
General disorders and administration site conditions
Influenza like illness
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
32.1%
9/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
2/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
General disorders and administration site conditions
Infusion site pain
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
General disorders and administration site conditions
Injection site reaction
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
General disorders and administration site conditions
Localised oedema
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
10.7%
3/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Hordeolum
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Herpes simplex reactivation
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
General disorders and administration site conditions
Mucosal inflammation
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
General disorders and administration site conditions
Non-cardiac chest pain
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
General disorders and administration site conditions
Non-pitting oedema
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
General disorders and administration site conditions
Oedema
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
General disorders and administration site conditions
Oedema peripheral
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.0%
2/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
9.0%
6/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
10.0%
3/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.2%
2/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
66.7%
2/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
3/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
General disorders and administration site conditions
Pain
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
General disorders and administration site conditions
Pyrexia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
2/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
3/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
1/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.0%
2/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
7.5%
5/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.2%
2/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
2/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
2/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
42.9%
12/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
2/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
2/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Hepatobiliary disorders
Biliary obstruction
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Hepatobiliary disorders
Cholangitis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Hepatobiliary disorders
Gallbladder obstruction
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Immune system disorders
Drug hypersensitivity
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Hepatobiliary disorders
Hepatic pain
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Hepatobiliary disorders
Hyperbilirubinaemia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.7%
2/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Hepatobiliary disorders
Portal vein thrombosis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Immune system disorders
Contrast media allergy
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Immune system disorders
Hypersensitivity
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Immune system disorders
Seasonal allergy
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
1/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Abdominal infection
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Abdominal wall abscess
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Bacteraemia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Infected skin ulcer
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
COVID-19 pneumonia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Candida infection
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
1/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Cellulitis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Conjunctivitis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
1/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Gastrointestinal disorders
Obstruction gastric
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Infection
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.2%
2/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Gastroenteritis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Genital candidiasis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Herpes zoster
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.0%
2/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.0%
2/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Human ehrlichiosis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Kidney infection
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Lower respiratory tract infection
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Lower respiratory tract infection viral
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Mucosal infection
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Nasopharyngitis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.2%
2/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Neutropenic infection
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Neutropenic sepsis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Oral candidiasis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Oral herpes
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Otitis externa
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Pharyngitis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Pharyngitis streptococcal
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
1/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.0%
2/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.0%
4/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Postoperative wound infection
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Rash pustular
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Respiratory syncytial virus infection
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
7.1%
2/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Rhinovirus infection
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Sepsis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Sinusitis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
1/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Skin infection
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Tooth infection
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Tuberculosis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
1/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.5%
3/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.0%
3/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.0%
2/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
17.9%
5/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Vaginal infection
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Viral upper respiratory tract infection
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Vulvovaginal candidiasis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Vulvovaginal mycotic infection
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Wound infection
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Injury, poisoning and procedural complications
Contusion
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.0%
2/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.0%
2/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
10.7%
3/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
2/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Injury, poisoning and procedural complications
Radiation proctitis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Injury, poisoning and procedural complications
Foot fracture
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Injury, poisoning and procedural complications
Infusion related reaction
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Injury, poisoning and procedural complications
Rib fracture
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Injury, poisoning and procedural complications
Jaw fracture
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Injury, poisoning and procedural complications
Ligament sprain
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Injury, poisoning and procedural complications
Nerve injury
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Injury, poisoning and procedural complications
Post procedural contusion
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Injury, poisoning and procedural complications
Procedural pain
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Infections and infestations
Folliculitis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Injury, poisoning and procedural complications
Shoulder fracture
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
1/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Injury, poisoning and procedural complications
Skin abrasion
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Injury, poisoning and procedural complications
Skin laceration
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Investigations
Neutrophil count increased
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Investigations
Red blood cell count decreased
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Investigations
SARS-CoV-2 test positive
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Investigations
Troponin T increased
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Investigations
Troponin increased
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Investigations
Weight decreased
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.0%
3/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.0%
2/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.7%
2/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
9.4%
3/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
2/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
10.7%
3/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
2/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Investigations
Weight increased
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
66.7%
4/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
66.7%
2/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
10/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
22.4%
15/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
5/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
2/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
8/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
35.7%
10/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
3/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
2/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.0%
2/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.0%
2/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.2%
2/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
7.1%
2/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
3/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Metabolism and nutrition disorders
Gout
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Metabolism and nutrition disorders
Hyperuricaemia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.7%
2/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Metabolism and nutrition disorders
Hypertriglyceridaemia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Metabolism and nutrition disorders
Hypoalbuminaemia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
2/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.7%
2/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Metabolism and nutrition disorders
Hypocalcaemia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.0%
2/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Metabolism and nutrition disorders
Hypochloraemia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.0%
2/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.0%
2/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
10.0%
3/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
66.7%
2/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
15.6%
5/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
7.1%
2/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
2/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.0%
2/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.2%
2/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.3%
4/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
2/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.0%
3/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.5%
3/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
13.3%
4/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.2%
2/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
7.1%
2/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
2/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Metabolism and nutrition disorders
Hypophosphataemia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.0%
2/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
9.4%
3/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Investigations
Aspartate aminotransferase increased
|
28.6%
2/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
13.4%
9/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
6/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
15.6%
5/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.3%
4/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
2/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Metabolism and nutrition disorders
Iron deficiency
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Injury, poisoning and procedural complications
Stoma site pain
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Injury, poisoning and procedural complications
Sunburn
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Injury, poisoning and procedural complications
Thermal burn
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Injury, poisoning and procedural complications
Tooth fracture
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Injury, poisoning and procedural complications
Upper limb fracture
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Injury, poisoning and procedural complications
Vascular access complication
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Investigations
Alanine aminotransferase increased
|
42.9%
3/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.9%
10/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
5/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
4/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
17.9%
5/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
3/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Investigations
Blood alkaline phosphatase increased
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.5%
3/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
5/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
9.4%
3/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
7.1%
2/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
2/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.5%
3/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
2/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Investigations
Blood creatinine increased
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
2/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
1/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.0%
3/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
10.4%
7/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.7%
2/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
10.7%
3/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Investigations
Blood iron decreased
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Investigations
Blood lactate dehydrogenase increased
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Investigations
Blood magnesium decreased
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Investigations
Blood potassium decreased
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Investigations
Breath sounds abnormal
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Investigations
Cardiac murmur
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Investigations
Electrocardiogram T wave abnormal
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Investigations
Lymphocyte count increased
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.0%
2/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.2%
2/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Renal and urinary disorders
Urge incontinence
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Renal and urinary disorders
Urinary hesitation
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
2/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.0%
3/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
7.5%
5/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
9.4%
3/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
10.7%
3/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
3/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal stiffness
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
7.1%
2/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
2/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cancer pain
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of skin
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.0%
2/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.5%
3/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Musculoskeletal and connective tissue disorders
Pain in jaw
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.7%
2/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Musculoskeletal and connective tissue disorders
Osteoporosis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer metastatic
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to abdominal cavity
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Seborrhoeic keratosis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Renal and urinary disorders
Urinary incontinence
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Nervous system disorders
Ataxia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Nervous system disorders
Brain fog
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Nervous system disorders
Cerebrovascular accident
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Nervous system disorders
Coordination abnormal
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Nervous system disorders
Dysgeusia
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.0%
2/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
7.5%
5/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.3%
4/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
2/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.0%
4/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.9%
10/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
10.0%
3/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
15.6%
5/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
21.4%
6/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
3/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Nervous system disorders
Dyskinesia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Nervous system disorders
Extrapyramidal disorder
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Nervous system disorders
Facial paralysis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Nervous system disorders
Headache
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
13.4%
9/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
13.3%
4/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
2/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
4/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
17.9%
5/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
66.7%
2/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
2/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
3/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Nervous system disorders
Hemiparesis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Nervous system disorders
Hyperaesthesia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Nervous system disorders
Hypoaesthesia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Nervous system disorders
Lethargy
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Nervous system disorders
Memory impairment
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Nervous system disorders
Neuralgia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Nervous system disorders
Neuropathy peripheral
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Nervous system disorders
Occipital neuralgia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Nervous system disorders
Paraesthesia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
1/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
2/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Nervous system disorders
Presyncope
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Nervous system disorders
Restless legs syndrome
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Nervous system disorders
Seizure
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Nervous system disorders
Somnolence
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.0%
2/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Nervous system disorders
Syncope
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
2/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Nervous system disorders
Tremor
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Psychiatric disorders
Abnormal dreams
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Psychiatric disorders
Insomnia
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.0%
2/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.5%
3/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
4/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
7.1%
2/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
3/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
2/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.0%
2/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.5%
3/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Psychiatric disorders
Depressed mood
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Psychiatric disorders
Depression
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.5%
3/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Psychiatric disorders
Hallucination
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Psychiatric disorders
Hallucination, visual
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Renal and urinary disorders
Bladder spasm
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Renal and urinary disorders
Dysuria
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.0%
2/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.7%
2/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Renal and urinary disorders
Glycosuria
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.0%
2/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
2/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Renal and urinary disorders
Hydronephrosis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Renal and urinary disorders
Micturition urgency
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Renal and urinary disorders
Nocturia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Renal and urinary disorders
Pollakiuria
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.0%
4/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
2/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Renal and urinary disorders
Polyuria
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Renal and urinary disorders
Proteinuria
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.7%
2/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Renal and urinary disorders
Urethral pain
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Metabolism and nutrition disorders
Polydipsia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
2/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.0%
3/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.0%
4/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
9.4%
3/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
7.1%
2/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
2/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
2/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Musculoskeletal and connective tissue disorders
Greater trochanteric pain syndrome
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.0%
2/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.0%
4/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
10.0%
3/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
2/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
4/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.3%
4/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Musculoskeletal and connective tissue disorders
Bursitis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Musculoskeletal and connective tissue disorders
Flank pain
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.0%
2/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
7.1%
2/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
2/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Musculoskeletal and connective tissue disorders
Groin pain
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.0%
2/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.0%
2/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.0%
2/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
9.4%
3/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Reproductive system and breast disorders
Penile oedema
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Renal and urinary disorders
Urinary retention
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Renal and urinary disorders
Urinary tract pain
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Renal and urinary disorders
Urine odour abnormal
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Reproductive system and breast disorders
Breast pain
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Reproductive system and breast disorders
Oedema genital
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Reproductive system and breast disorders
Pelvic pain
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.2%
2/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Reproductive system and breast disorders
Scrotal oedema
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Reproductive system and breast disorders
Scrotal ulcer
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Reproductive system and breast disorders
Vaginal discharge
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Reproductive system and breast disorders
Vaginal haemorrhage
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Reproductive system and breast disorders
Vulvovaginal pain
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Reproductive system and breast disorders
Vulvovaginal pruritus
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Respiratory, thoracic and mediastinal disorders
Asthma
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
2/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
1/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.0%
4/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
5/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
18.8%
6/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.3%
4/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
3/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Respiratory, thoracic and mediastinal disorders
Dysphonia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
66.7%
4/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
66.7%
2/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
2/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.0%
4/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.9%
14/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
23.3%
7/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
66.7%
2/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
2/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
15.6%
5/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
2/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
21.4%
6/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
58.3%
7/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary pain
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
100.0%
1/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Respiratory, thoracic and mediastinal disorders
Haemoptysis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Respiratory, thoracic and mediastinal disorders
Increased viscosity of upper respiratory secretion
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.0%
2/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.2%
2/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.2%
2/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Respiratory, thoracic and mediastinal disorders
Pharyngeal erythema
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.0%
2/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
2/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinitis allergic
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.7%
2/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Respiratory, thoracic and mediastinal disorders
Sinus pain
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Respiratory, thoracic and mediastinal disorders
Sleep apnoea syndrome
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Respiratory, thoracic and mediastinal disorders
Sneezing
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Respiratory, thoracic and mediastinal disorders
Upper-airway cough syndrome
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Respiratory, thoracic and mediastinal disorders
Wheezing
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Vascular disorders
Hypertension
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.0%
2/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.0%
2/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
2/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
53.6%
15/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
66.7%
2/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
3/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
6/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
28.6%
2/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Skin and subcutaneous tissue disorders
Blister
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Skin and subcutaneous tissue disorders
Dermatitis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Skin and subcutaneous tissue disorders
Decubitus ulcer
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Skin and subcutaneous tissue disorders
Dermatitis acneiform
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.5%
3/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Skin and subcutaneous tissue disorders
Skin hyperpigmentation
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Skin and subcutaneous tissue disorders
Drug eruption
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Skin and subcutaneous tissue disorders
Ecchymosis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Skin and subcutaneous tissue disorders
Eczema
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Skin and subcutaneous tissue disorders
Erythema
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Skin and subcutaneous tissue disorders
Nail disorder
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Skin and subcutaneous tissue disorders
Nail ridging
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Skin and subcutaneous tissue disorders
Night sweats
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Skin and subcutaneous tissue disorders
Pain of skin
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Skin and subcutaneous tissue disorders
Palmar-plantar erythrodysaesthesia syndrome
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
7.1%
2/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
2/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Skin and subcutaneous tissue disorders
Photosensitivity reaction
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.5%
1/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.5%
3/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
7/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
2/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
41.7%
5/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
2/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.0%
2/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.5%
3/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.7%
2/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
10.7%
3/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Skin and subcutaneous tissue disorders
Rash macular
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
2/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
7.5%
5/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.7%
2/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
6.2%
2/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
40.0%
2/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
7/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
3/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Skin and subcutaneous tissue disorders
Rash papular
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Skin and subcutaneous tissue disorders
Rash pruritic
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Skin and subcutaneous tissue disorders
Rosacea
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Skin and subcutaneous tissue disorders
Skin discolouration
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Skin and subcutaneous tissue disorders
Skin exfoliation
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Skin and subcutaneous tissue disorders
Skin ulcer
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Surgical and medical procedures
Tooth restoration
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Vascular disorders
Deep vein thrombosis
|
14.3%
1/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.0%
1/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Vascular disorders
Embolism
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
25.0%
1/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
4.5%
3/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Vascular disorders
Flushing
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
10.7%
3/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Vascular disorders
Haematoma
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Vascular disorders
Hot flush
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Vascular disorders
Hypotension
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
12.0%
3/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.0%
2/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
50.0%
1/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
33.3%
1/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
9.4%
3/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
20.0%
1/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.6%
1/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
8.3%
1/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Vascular disorders
Hypovolaemic shock
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Vascular disorders
Lymphoedema
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
16.7%
1/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Vascular disorders
May-Thurner syndrome
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.3%
1/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Vascular disorders
Orthostatic hypotension
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Vascular disorders
Peripheral arterial occlusive disease
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
1.5%
1/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
|
Vascular disorders
Varicose vein
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/8 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/1 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/4 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/25 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/67 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/30 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
3.1%
1/32 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/5 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/28 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/3 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/2 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/6 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/12 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
0.00%
0/7 • Up to 4.5 years
Treatment-emergent adverse events (TEAE) are those events that occur or worsen on or after the first dose of study drug up through 30 days post the last dose (or cross over to a different module) or the start of subsequent anticancer therapy. Treatment-related serious adverse events are included in TEAEs and reported indefinitely.
|
Additional Information
Repare Therapeutics Medical Monitor
Repare Therapeutics Inc
Phone: 1 (857) 340-5402
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place